Pediatric Neurology Devices Market By Product Type (Neurodiagnostic Devices, Neuromodulation Devices, Neuroimaging Devices, Monitoring Devices, Others); By Application (Epilepsy Monitoring and Treatment, Cerebral Palsy and Movement Disorders, Traumatic Brain Injury Management, Neuro-Oncology, Developmental and Behavioral Disorders); By End User (Hospitals, Specialty Neurology Clinics, Research & Academic Institutions, Ambulatory Surgical Centers, Home Care Settings); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Pediatric Neurology Devices Market: Pediatric Neurological Care Devices & Technologies

The Global Pediatric Neurology Devices Market will witness a robust CAGR of 8.7%, valued at $2.86 billion in 2025, and is projected to reach $4.72 billion by 2032, according to Strategic Market Research.

 

Pediatric neurology devices include diagnostic, monitoring, imaging, and implantable technologies used in the neurological care of infants, children, and adolescents. The market covers EEG and video-EEG equipment, neuroimaging devices, vagus nerve stimulation (VNS), deep-brain stimulation (DBS), cerebrospinal-fluid shunts, intrathecal drug-delivery pumps, and intracranial-pressure (ICP) monitoring systems.

 

Demand is increasing as pediatric neurological care moves toward earlier diagnosis, longer-term monitoring, and specialized treatment for difficult-to-control conditions. Epilepsy provides one of the largest recurring diagnostic populations, while hydrocephalus, severe spasticity, dystonia, traumatic brain injury, and pediatric brain tumors create additional demand for implants, monitoring systems, and imaging. Repeat EEG studies, shunt revisions, implant programming, device replacements, and pump refills also extend demand beyond the initial procedure.

 

CDC estimates that 456,000 U.S. children aged 17 or younger had active epilepsy in 2022, while global research estimated 6.096 million children aged 0–14 with idiopathic epilepsy in 2021. Hydrocephalus research has estimated nearly 400,000 new pediatric cases annually worldwide, while CDC surveillance reported cerebral palsy prevalence of 2.4 per 1,000 eight-year-old children across five U.S. surveillance communities in 2022. These populations create a significant clinical base for neurological diagnosis, monitoring, surgical devices, and selected implantable therapies.

 

The pediatric neurology medical device landscape is limited by small patient populations, complex regulatory pathways, and high development costs, but is advancing across neuromodulation, wearables, brain-machine interfaces, and AI-based diagnostics. The FDA oversees these devices through standard PMA pathways and Humanitarian Device Exemptions (HDEs) for rare pediatric conditions. Established therapies include vagus nerve stimulation (VNS), with LivaNova’s VNS Therapy System approved for children aged 4+ with drug-resistant epilepsy, and deep brain stimulation (DBS), where Medtronic’s Activa Neurostimulator is approved via HDE for pediatric primary dystonia in patients aged 7+. These provide key alternatives when medication is insufficient.

 

Newer and emerging technologies are expanding treatment options, including Theranica’s Nerivio wearable neuromodulation device for pediatric migraine, which is being studied in younger populations, and AI-enabled EEG and seizure detection tools that improve diagnostic accuracy. Some adult-approved devices, such as NeuroPace’s RNS system and the Pipeline Embolization Device, are also used off-label in children with severe epilepsy or intracranial aneurysms, highlighting unmet pediatric needs. The pipeline is increasingly focused on growth-adaptive and long-term solutions, including Axoft’s FDA Breakthrough-designated flexible brain-machine interface and expandable bioelectronic transistor arrays developed with institutions like CHOC Children’s, designed to adapt to anatomical growth and reduce repeat surgeries. Additionally, responsive and closed-loop neuromodulation is being studied in patients under 18 to expand FDA indications. Overall, the field is shifting toward more personalized, minimally invasive, and durable pediatric neurological technologies.

 

Pediatric Neurology Devices Market By Product Type

Neurodiagnostic Devices

Neurodiagnostic devices accounted for 34.0% of the Pediatric Neurology Devices Market in 2025, representing $0.97 billion, and are projected to grow at a CAGR of 8.6% during 2026–2032. This was the largest product segment, supported by widespread use of EEG, video-EEG, evoked-potential systems, and specialized electrodes in epilepsy assessment and neurological monitoring. Natus supports pediatric routine, ambulatory, long-term, ICU, and home EEG workflows, illustrating how neurological diagnostics can generate recurring demand across several care settings.

Demand is particularly strong in epilepsy, where EEG may be used at diagnosis, during long-term monitoring, and before surgical intervention. Nihon Kohden expanded its position in this area through its 2024 acquisition of a 71.4% interest in NeuroAdvanced, the parent of Ad-Tech Medical Instrument Corporation, strengthening its access to specialized intracranial electrodes used in epilepsy diagnosis and treatment.

 

Neuromodulation Devices

Neuromodulation devices held 25.0% of the market in 2025, equal to approximately $0.72 billion, and are expected to record the fastest product-type CAGR of 10.1% through 2032. The segment includes VNS and DBS systems used in selected children with drug-resistant epilepsy and severe movement disorders.

LivaNova's VNS Therapy has an established U.S. pediatric pathway for drug-resistant epilepsy in children aged four years and older, while Medtronic's U.S. DBS pathway covers generalized dystonia in pediatric patients aged 12 years and above. Growing experience at epilepsy and movement-disorder centers is supporting wider use of neuromodulation among carefully selected patients who remain inadequately controlled with conventional treatment.

 

Neuroimaging Devices

Neuroimaging devices represented 18.0% of the market in 2025, equivalent to $0.51 billion, and are projected to expand at a CAGR of 7.8%. Demand comes from neurological assessment, surgical planning, brain-tumor evaluation, structural abnormalities, trauma, and complex epilepsy cases.

Pediatric neuro-oncology creates recurring imaging requirements from diagnosis and surgical planning through treatment assessment and surveillance. Imaging demand is also reinforced by the expansion of tertiary pediatric hospitals and specialist neurological services capable of managing complex neurological and neurosurgical cases.

 

Monitoring Devices

Monitoring devices captured 16.0% of the market in 2025, generating $0.46 billion, and are forecast to grow at a CAGR of 8.9% through 2032. This category includes ICP monitoring and related neurological monitoring equipment used primarily in intensive-care, trauma, and neurosurgical environments.

The Brain Trauma Foundation supports ICP monitoring within the management pathway for severe pediatric TBI. Integra LifeSciences has strengthened product availability through its CereLink ICP Monitoring System, which is indicated where direct intracranial-pressure monitoring is required.

 

Others

Other pediatric neurology devices accounted for 7.0% of the market in 2025, valued at $0.20 billion, and are projected to grow at a CAGR of 6.5%. This segment includes specialized neurological electrodes, drug-delivery systems, accessories, and smaller device categories supporting diagnostic and neurosurgical procedures. Demand remains closely linked to growth in specialist pediatric neurological care.

 

Pediatric Neurology Devices Market By Application

Epilepsy Monitoring and Treatment

Epilepsy monitoring and treatment dominated the application segment with a 38.0% share in 2025, representing $1.09 billion, and is expected to grow at a CAGR of 9.4%. Demand spans EEG, video-EEG, invasive electrodes, VNS, imaging, and presurgical neurological evaluation.

CDC estimates 456,000 U.S. children aged 17 or younger had active epilepsy in 2022, creating a large recurring diagnostic population. Device demand increases further among children with drug-resistant seizures who move from medication management into long-term monitoring, invasive assessment, surgery, or neuromodulation.

 

Cerebral Palsy and Movement Disorders

Cerebral palsy and movement disorders accounted for 22.0% of the market in 2025, or $0.63 billion, with an estimated CAGR of 8.8% through 2032. Demand includes neurological assessment, movement monitoring, DBS, and implantable intrathecal drug-delivery systems for selected severe cases.

CDC surveillance reported cerebral palsy prevalence of approximately 2.4 per 1,000 eight-year-old children across five U.S. communities in 2022. Medtronic's SynchroMed III implantable drug-delivery system addresses severe spasticity, while its DBS platform provides another device pathway for selected pediatric dystonia patients.

 

Traumatic Brain Injury Management

Traumatic brain injury management held 16.0% of the market in 2025, valued at $0.46 billion, and is projected to grow at a CAGR of 8.3%. Demand is concentrated in pediatric emergency departments, trauma centers, ICUs, and neurosurgical units where severe injuries can require invasive neurological monitoring.

Research cited in the supporting evidence estimates approximately 5.4 million pediatric TBI events annually worldwide, while U.S. data recorded more than 17,500 pediatric TBI hospitalizations in 2017. Severe cases constitute the main addressable population for ICP sensors and related neurocritical-care equipment.

 

Neuro-Oncology

Neuro-oncology represented 13.0% of the market in 2025, generating $0.37 billion, and is expected to expand at a CAGR of 9.1%. Imaging, neurological monitoring, surgical navigation, and neurosurgical equipment account for much of device utilization in this application.

Treatment is concentrated at specialist pediatric oncology and neurosurgical centers, where patients may undergo repeated imaging and neurological assessment across diagnosis, surgery, treatment, and surveillance. Growing use of image-guided cranial procedures also expands the relevance of surgical-navigation companies to this segment.

 

Developmental and Behavioral Disorders

Developmental and behavioral disorders accounted for 11.0% of the market in 2025, equal to $0.31 billion, and are projected to grow at a CAGR of 6.6%. Device demand is concentrated in neurological evaluation and selected EEG or imaging investigations where clinicians investigate neurological conditions or associated seizure disorders. Lower use of implantable therapies keeps growth below epilepsy, neuro-oncology, and movement-disorder applications.

 

Pediatric Neurology Devices Market By End User

Hospitals

Hospitals led the market with a 49.0% share in 2025, representing $1.40 billion, and are projected to grow at a CAGR of 8.6%. Pediatric hospitals and tertiary medical centers concentrate EEG monitoring, neuroimaging, neurosurgery, ICP monitoring, shunt procedures, DBS, and VNS implantation within one care environment.

Hospital leadership reflects the need for pediatric neurologists, neurosurgeons, intensive-care teams, operating rooms, specialist diagnostic equipment, and postoperative management for implantable neurological devices.

 

Specialty Neurology Clinics

Specialty neurology clinics accounted for 21.0% of the market in 2025, valued at $0.60 billion, and are expected to grow at a CAGR of 9.1%. Epilepsy and movement-disorder clinics support repeated diagnostic monitoring, implant programming, neurological assessment, and long-term follow-up.

Increasing concentration of difficult epilepsy and movement-disorder cases within specialist networks is supporting demand for EEG systems, electrodes, software, and neuromodulation-related services.

 

Research & Academic Institutions

Research and academic institutions represented 12.0% of the market in 2025, or $0.34 billion, and are projected to grow at a CAGR of 7.5%. University hospitals and neuroscience programs use neurodiagnostic, imaging, stimulation, and monitoring technologies in neurological research, clinical studies, surgical planning, and development of new treatment pathways.

Their role is particularly important in rare neurological disorders and complex pediatric neurosurgery, where patients and specialist expertise are concentrated at major academic centers.

 

Ambulatory Surgical Centers

Ambulatory surgical centers held 10.0% of the market in 2025, representing $0.29 billion, and are forecast to grow at a CAGR of 8.8%. Their role is increasing for suitable neurological procedures and implant-related care that can be performed outside conventional inpatient environments.

Growth depends on procedure complexity, reimbursement, surgical infrastructure, and whether pediatric patients can safely receive treatment without the broader resources of a tertiary hospital.

 

Home Care Settings

Home care settings accounted for 8.0% of the market in 2025, valued at $0.23 billion, and are projected to record the fastest end-user CAGR of 10.3%. Expansion is being supported by ambulatory EEG, portable monitoring, longer-duration recordings, and remote neurological review.

Natus' BRAIN QUICK Ambulatory and Trex HD platforms illustrate this shift, supporting ambulatory or home-based EEG alongside pediatric hospital monitoring. Home monitoring expands the period over which neurological activity can be observed without requiring prolonged inpatient admission.

 

Pediatric Neurology Devices Market By Geography

North America

North America dominated the Pediatric Neurology Devices Market with a 41.0% share in 2025, representing $1.17 billion, and is projected to grow at a CAGR of 8.3%. The region benefits from advanced pediatric hospitals, established epilepsy centers, neurological research programs, reimbursement coverage, and early use of neuromodulation and neurocritical-care technologies.

The United States provides particularly strong commercial and regulatory evidence across epilepsy VNS, pediatric dystonia DBS, shunting, EEG, and neurological monitoring. LivaNova's U.S. VNS indication extends to children aged four and above, while Medtronic supports pediatric DBS for generalized dystonia from age 12.

 

Europe

Europe accounted for 26.0% of the market in 2025, valued at $0.74 billion, and is forecast to grow at a CAGR of 7.9%. Demand is supported by specialist children's hospitals, epilepsy programs, public healthcare systems, and established neurological-device adoption across major Western European economies.

The region also has pediatric neuromodulation opportunities beyond those available under some U.S. indications. Boston Scientific's European Vercise DBS labeling, for example, includes treatment of intractable primary and secondary dystonia in patients seven years and older.

 

Asia-Pacific

Asia-Pacific represented 24.0% of the market in 2025, generating $0.69 billion, and is projected to be the fastest-growing region with a CAGR of 10.3% through 2032. Expansion of tertiary hospitals, a large pediatric population, improving neurological diagnostic capacity, and investment in medical equipment are supporting demand.

Nihon Kohden's expansion in neurological diagnostics, including its 2024 Ad-Tech transaction, strengthens its ability to serve epilepsy-monitoring and invasive-electrode demand across international healthcare systems. The company reported that international sales growth in recent reporting was supported by neurology products including Ad-Tech.

 

Latin America

Latin America held 5.5% of the market in 2025, representing $0.16 billion, and is projected to grow at a CAGR of 8.9%. Pediatric hydrocephalus and other neurological disorders create substantial clinical need, while investment in specialist hospitals is gradually improving access to diagnostic and neurosurgical technologies.

Global epidemiological research has shown hydrocephalus burden to be comparatively high in parts of Latin America, increasing the requirement for CSF-management capacity, pediatric neurosurgery, and long-term follow-up.

 

Middle East & Africa

The Middle East & Africa accounted for 3.5% of the market in 2025, valued at $0.10 billion, and is projected to grow at a CAGR of 7.7%. Demand remains concentrated in major urban hospitals and specialist centers, while access to pediatric neurology and neurosurgery varies considerably across countries.

Hydrocephalus represents an important device-related neurological burden in the region. Expansion of tertiary hospitals, neurodiagnostic capacity, and neurosurgical services can therefore increase adoption of EEG equipment, CSF-management products, and neurological monitoring technologies.

 

Recurring Device Use Strengthens Long-Term Market Demand

An important feature of the Pediatric Neurology Devices Market is the combination of new-device demand and repeated utilization. EEG studies may be repeated as seizure patterns change; VNS and DBS systems require programming and eventual component replacement; intrathecal pumps require recurring refills; and hydrocephalus shunts can require revision surgery.

Hydrocephalus is particularly important because approximately 50% of pediatric shunts have been reported to fail within two years, producing recurring neurosurgical demand. Neuromodulation similarly creates long-term device-management requirements after implantation, adding replacement, programming, and follow-up demand to initial procedure revenue.

 

Key Companies Driving the Pediatric Neurology Devices Market

Medtronic – Leading Global Player in Pediatric Neurology Devices Across Hydrocephalus, DBS, and Drug Delivery

Medtronic has one of the broadest directly relevant portfolios across pediatric neurology, spanning CSF management, DBS, and implantable drug delivery. Its PS Medical Strata adjustable-pressure shunt is used for hydrocephalus in children and adults, while the company's DBS system has a U.S. pathway for generalized dystonia in pediatric patients aged 12 years and above. SynchroMed III adds an implantable drug-delivery platform for severe spasticity.

This breadth gives Medtronic exposure to several revenue streams rather than a single neurological condition. Hydrocephalus creates initial and revision demand for shunt systems, dystonia creates a smaller high-value DBS opportunity, and severe spasticity adds recurring pump-management activity. The company is therefore positioned across both neurosurgical and long-duration implant pathways.

 

LivaNova – Pediatric-Focused Leader in VNS Therapy for Drug-Resistant Epilepsy

LivaNova is one of the most pediatric-specific neuromodulation participants through its VNS Therapy franchise for drug-resistant epilepsy. Its U.S. indication covers children aged four years and older with refractory partial-onset seizures, connecting the company directly with a pediatric population that remains inadequately controlled after medication.

VNS gives LivaNova a differentiated position because epilepsy represents the largest application segment in this analysis. Demand extends beyond the initial implant through patient follow-up and eventual generator replacement, while continued pediatric clinical evidence strengthens VNS adoption within specialist epilepsy centers.

 

Integra LifeSciences – Key Player in Neurocritical Care and Pediatric Hydrocephalus Management

Integra LifeSciences participates across neurocritical care and CSF management through CereLink ICP monitoring and Codman/Certas hydrocephalus products. CereLink sensors are indicated when direct intracranial-pressure monitoring is required, while the Certas Plus portfolio extends Integra's presence in programmable CSF management.

These products place Integra in two procedure-intensive areas: acute neurological monitoring following severe brain injury and longer-term hydrocephalus management. The 2024 U.S. CereLink relaunch also returned an important product platform to the company's neurological-monitoring business.

 

Stryker Corporation – Advancing Pediatric Neurosurgery Through Image-Guided Navigation Systems

Stryker contributes to pediatric neurology primarily through cranial navigation, neurosurgical access, visualization, and procedural technologies rather than chronic implant therapy. Its Q Guidance System with Cranial Guidance Software supports image-based planning and intraoperative navigation for complex cranial procedures, with Stryker specifically highlighting biopsies and shunt placements when the platform was commercially launched in 2023.

This gives Stryker relevance to pediatric neuro-oncology, hydrocephalus surgery, and other complex neurosurgical procedures. Greater use of image-guided surgery at tertiary pediatric centers can increase demand for navigation platforms alongside the implants and monitoring equipment supplied by other market participants.

 

Natus Medical – Dominant Force in Pediatric EEG and Neurodiagnostic Monitoring Solutions

Natus Medical has a strong position in the diagnostic side of pediatric neurology through EEG, long-term video monitoring, ambulatory EEG, ICU monitoring, and neonatal brain monitoring. Its BRAIN QUICK LTM system supports pediatric long-term studies, Trex HD covers pediatric routine, hospital, and home ambulatory EEG, and the Olympic Brainz platform serves neonatal cerebral-function monitoring.

Natus is particularly exposed to recurring diagnostic demand rather than implant procedures. Growth in epilepsy-monitoring units, NICUs, ambulatory EEG, and home neurological assessment can increase utilization across its equipment, software, and associated monitoring ecosystem.

 

Abbott Laboratories – Expanding Neuromodulation Technology Platform Influencing Pediatric Neurology Innovation

Abbott is an important broader neuromodulation competitor through its Infinity DBS platform and connected neurological-device capabilities. The company participates in deep-brain stimulation for movement disorders and has invested in remote and digitally connected management through its NeuroSphere ecosystem.

Its currently highlighted U.S. DBS applications are centered primarily on adult movement disorders, making Abbott's role in this market more relevant as a competitive neuromodulation technology platform than as a major pediatric-labeled franchise. Its experience in implantable stimulation, programming, connectivity, and device management nevertheless influences technology expectations across the broader neurological-device industry.

 

Boston Scientific – Growing Pediatric Presence in Deep Brain Stimulation for Movement Disorders

Boston Scientific participates in neuromodulation through its Vercise DBS portfolio and has direct pediatric-age relevance in selected international markets. European labeling for Vercise DBS includes treatment of intractable primary and secondary dystonia in patients seven years of age and older, giving the company a defined role in younger movement-disorder populations outside its more adult-focused U.S. DBS indication.

Boston Scientific therefore adds competitive pressure in the higher-growth neuromodulation segment, particularly where DBS eligibility includes younger patients. Competition is shaped by stimulation capability, programming, implant longevity, clinical evidence, and the ability of specialist centers to support long-term management.

 

Nihon Kohden – Strengthening Leadership in EEG and Invasive Epilepsy Diagnostics

Nihon Kohden is strengthening its position across EEG and invasive epilepsy diagnostics. In November 2024, the company acquired a 71.4% stake in NeuroAdvanced, the parent of Ad-Tech Medical Instrument Corporation, adding specialized intracranial electrodes to Nihon Kohden's established neurodiagnostic portfolio.

The combination expands Nihon Kohden's presence across routine neurological recording, long-term EEG, intracranial monitoring, brain mapping, and epilepsy evaluation. In 2025, the company continued to present an increasingly integrated EEG portfolio and highlighted further integration between Ad-Tech electrodes and Nihon Kohden systems.

Together, these companies illustrate the different commercial models within pediatric neurology devices. Medtronic, LivaNova, and selected Boston Scientific products participate more directly in implantable neuromodulation; Integra and Medtronic have strong neurosurgical and CSF-management exposure; Natus and Nihon Kohden are more concentrated in neurological diagnostics; and Stryker contributes through surgical navigation and cranial procedures. Abbott remains an important broader neuromodulation technology competitor. As pediatric neurological care becomes more specialized, companies able to participate across diagnosis, intervention, monitoring, and long-term device management are positioned to capture a larger share of spending at tertiary hospitals and specialist neurology centers.

 

Competitive Landscape

Competition in pediatric neurology devices is spread across diagnostic systems, neuromodulation, CSF management, neurocritical-care monitoring, surgical navigation, and implantable drug-delivery products rather than being controlled by one product class. Companies with a direct pediatric presence include Medtronic in hydrocephalus, dystonia DBS, and severe-spasticity delivery systems; LivaNova in pediatric VNS; Integra LifeSciences in CSF management and ICP monitoring; and Natus and Nihon Kohden in neurological diagnostics.

Larger neurosurgical and neuromodulation companies also influence competition through adjacent product categories. Stryker participates through cranial navigation and neurosurgical technologies, Abbott through its broader DBS and neuromodulation portfolio, and Boston Scientific through Vercise DBS, including pediatric-age dystonia indications in European labeling.

 

Pediatric Neurology Devices Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 2.86 Billion
Revenue Forecast in 2032	USD 4.72 Billion
Overall Growth Rate	CAGR of 8.7% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Application, By End User, By Geography
By Product Type	Neurodiagnostic Devices, Neuromodulation Devices, Neuroimaging Devices, Monitoring Devices, Others
By Application	Epilepsy Monitoring and Treatment, Cerebral Palsy and Movement Disorders, Traumatic Brain Injury Management, Neuro-Oncology, Developmental and Behavioral Disorders
By End User	Hospitals, Specialty Neurology Clinics, Research & Academic Institutions, Ambulatory Surgical Centers, Home Care Settings
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising diagnosis and long-term monitoring of pediatric epilepsy and neurological disorders; growing adoption of VNS, DBS, ambulatory EEG, ICP monitoring, and other advanced neurological technologies; increasing investment in specialized pediatric neurology and neurosurgical infrastructure; recurring demand from implant programming, shunt revisions, pump refills, device replacement, and repeat diagnostic monitoring
Customization Option	Available upon request